The CANTOS trial is the largest clinical trial of any cytokine blocker or biologic performed to date with more than 20,000-patient-year exposure, providing the opportunity to determine with precision the magnitude of increased risk of infection expected with IL-1 blockade. The gene discussed is IL1A; the disease is infection.